1
|
Paulson KG, Ravi V, Rubin BP, Park M, Loggers ET, Cranmer LD, Wagner MJ. Incidence, demographics, and survival of malignant hemangioendothelioma in the United States. Cancer Med 2023; 12:15101-15106. [PMID: 37260142 PMCID: PMC10417180 DOI: 10.1002/cam4.6181] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2023] [Revised: 05/15/2023] [Accepted: 05/20/2023] [Indexed: 06/02/2023] Open
Abstract
BACKGROUND Malignant hemangioendothelioma is an endothelial cancer with heterogeneous clinical behavior that can range from indolent to aggressive, of which the majority are epithelioid (EHE). Its incidence and demographics have not been previously well defined in a large cohort. METHODS This retrospective analysis used the US Cancer Statistics National Program of Cancer Registries - Surveillance Epidemiology End Results (SEER) combined database to identify patients in the US newly diagnosed with hemangioendothelioma between the years of 2001 and 2017 (n = 1986). Survival analyses were performed on a subset of patients within the SEER-18 database with survival information available (n = 417). Outcomes included incidence, demographics of patients newly diagnosed with hemangioendothelioma, extent of disease at presentation, and overall survival. RESULTS The incidence of hemangioendothelioma in the US is 0.4 cases per million person-years. Although cases rose to 122 newly diagnosed in the year 2017 (90 EHE, 32 other hemangioendothelioma), incidence rates were stable. Skin and connective tissues were the most common presenting sites (33.4%), followed by liver (24.5%), lung (17.6%), and bone (12.5%). Median age at diagnosis was 55 years; 27.2% of patients were pediatric, adolescent, or young adult (<40 years). At presentation, 36.4% of patients had localized disease; 21.6% presented with regional and 41.7% with distant metastases. Observed survival at 3 years was 79.7%, 70.7%, and 46.0% for patients presenting with local, regional, and distant disease and most deaths occurred within the first 2 years. CONCLUSIONS Malignant hemangioendothelioma is ultra-rare but meaningfully impacts affected patients. These data may provide benchmarks for comparison of new approaches to hemangioendothelioma therapy and highlight poor survival outcomes.
Collapse
Affiliation(s)
- Kelly G. Paulson
- Medical OncologyProvidence‐Swedish Cancer InstituteSeattleWashingtonUSA
| | - Vinod Ravi
- Sarcoma Medical OncologyMD Anderson Cancer CenterHoustonTexasUSA
| | - Brian P. Rubin
- Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland ClinicClevelandOhioUSA
| | - Min Park
- Medical OncologyProvidence‐Swedish Cancer InstituteSeattleWashingtonUSA
| | - Elizabeth T. Loggers
- Clinical Research DivisionFred Hutchinson Cancer CenterSeattleWashingtonUSA
- Division of Medical OncologyUniversity of WashingtonSeattleWashingtonUSA
| | - Lee D. Cranmer
- Clinical Research DivisionFred Hutchinson Cancer CenterSeattleWashingtonUSA
- Division of Medical OncologyUniversity of WashingtonSeattleWashingtonUSA
| | - Michael J. Wagner
- Clinical Research DivisionFred Hutchinson Cancer CenterSeattleWashingtonUSA
- Division of Medical OncologyUniversity of WashingtonSeattleWashingtonUSA
| |
Collapse
|
2
|
Wolff DT, Monaghan TF, Gordon DJ, Michelson KP, Jones T, Khargi R, Smith MT, Maffucci F, Kwun H, Suss NR, Winer AG. Racial Differences in Incident Genitourinary Cancer Cases Captured in the National Cancer Database. ACTA ACUST UNITED AC 2021; 57:medicina57070671. [PMID: 34209546 PMCID: PMC8303448 DOI: 10.3390/medicina57070671] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2021] [Revised: 06/18/2021] [Accepted: 06/22/2021] [Indexed: 11/16/2022]
Abstract
Background and Objectives: The National Cancer Database (NCDB) captures nearly 70% of all new cancer diagnoses in the United States, but there exists significant variation in this capture rate based on primary tumor location and other patient demographic factors. Prostate cancer has the lowest coverage rate of all major cancers, and other genitourinary malignancies likewise fall below the average NCDB case coverage rate. We aimed to explore NCDB coverage rates for patients with genitourinary cancers as a function of race. Materials and Methods: We compared the incidence of cancer cases in the NCDB with contemporary United States Cancer Statistics data. Results: Across all malignancies, American Indian/Alaskan Natives subjects demonstrated the lowest capture rates, and Asian/Pacific Islander subjects exhibited the second-lowest capture rates. Between White and Black subjects, capture rates were significantly higher for White subjects overall and for prostate cancer and kidney cancer in White males, but significantly higher for bladder cancer in Black versus White females. No significant differences were observed in coverage rates for kidney cancer in females, bladder cancer in males, penile cancer, or testicular cancer in White versus Black patients. Conclusions: Differential access to Commission on Cancer-accredited treatment facilities for racial minorities with genitourinary cancer constitutes a unique avenue for health equity research.
Collapse
Affiliation(s)
- Dylan T. Wolff
- Department of Urology, Wake Forest School of Medicine, Winston-Salem, NC 27101, USA;
| | - Thomas F. Monaghan
- Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
- Correspondence:
| | - Danielle J. Gordon
- Department of Urology, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, USA; (D.J.G.); (R.K.); (M.T.S.); (A.G.W.)
- Department of Urology, Kings County Hospital Center, Brooklyn, NY 11203, USA
| | - Kyle P. Michelson
- Department of Urology, University of South Florida, Tampa, FL 33606, USA;
| | - Tashzna Jones
- Department of Urology, Yale University School of Medicine, New Haven, CT 06520, USA;
| | - Raymond Khargi
- Department of Urology, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, USA; (D.J.G.); (R.K.); (M.T.S.); (A.G.W.)
- Department of Urology, Kings County Hospital Center, Brooklyn, NY 11203, USA
| | - Matthew T. Smith
- Department of Urology, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, USA; (D.J.G.); (R.K.); (M.T.S.); (A.G.W.)
- Department of Urology, Kings County Hospital Center, Brooklyn, NY 11203, USA
| | - Fenizia Maffucci
- Department of Urology, Temple University Hospital, Philadelphia, PA 19104, USA;
| | - Hyezo Kwun
- Division of Urology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA 19104, USA;
| | - Nicholas R. Suss
- Department of Surgery, University of Chicago, Chicago, IL 60637, USA;
| | - Andrew G. Winer
- Department of Urology, SUNY Downstate Health Sciences University, Brooklyn, NY 11203, USA; (D.J.G.); (R.K.); (M.T.S.); (A.G.W.)
- Department of Urology, Kings County Hospital Center, Brooklyn, NY 11203, USA
| |
Collapse
|
3
|
White DL, Thrift AP, Kanwal F, Davila J, El-Serag HB. Incidence of Hepatocellular Carcinoma in All 50 United States, From 2000 Through 2012. Gastroenterology 2017; 152:812-820.e5. [PMID: 27889576 PMCID: PMC5346030 DOI: 10.1053/j.gastro.2016.11.020] [Citation(s) in RCA: 303] [Impact Index Per Article: 43.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/13/2016] [Revised: 11/03/2016] [Accepted: 11/15/2016] [Indexed: 02/07/2023]
Abstract
BACKGROUND & AIMS The incidence and mortality of hepatocellular carcinoma (HCC) have been reported to be plateauing in the United States. The United States has large racial, ethnic, and regional variation; we collected data from all 50 states to better analyze changes in HCC incidence in the entire United States. METHODS We collected data from the US Cancer Statistics registry, which covers 97% of the population, and calculated adjusted incidence rates. We assessed annual trends among sociodemographic and geographic subgroups using joinpoint analysis. RESULTS HCC incidence increased from 4.4/100,000 in 2000 to 6.7/100,000 in 2012, increasing by 4.5% (95% confidence interval [CI], 4.3%-4.7%) annually between 2000 and 2009, but only by 0.7% annually (95% CI, -0.2% to 1.6%) from 2010 through 2012. The average annual percentage change (AAPC) between 2000 and 2012 was higher in men (increase, 3.7%) than in women (increase, 2.7%), and highest in 55- to 59-year-old individuals (AAPC, 8.9%; 95% CI, 7.1%-10.7%) and 60- to 64-year-old individuals (AAPC, 6.4%; 95% CI, 4.7%-8.2%). By 2012, rates in Hispanics surpassed those in Asians, and rates in Texas surpassed those in Hawaii (9.71/100,000 vs 9.68/100,000). Geographic variation within individual race and ethnic groups was observed, but rates were highest in all major race and ethnic groups in Texas. CONCLUSIONS In an analysis of the incidence of HCC in all 50 US states, we found the rate of increase in HCC to have slowed from 2010 through 2012. However, incidence is increasing in subgroups such as men ages 55 to 64 years old-especially those born in the peak era of hepatitis C virus infection and among whites/Caucasians. Rates in Hispanics have surpassed those in Asian Americans. We observed geographic differences, with Texas having the highest age-adjusted HCC rates nationwide.
Collapse
Affiliation(s)
- Donna L White
- Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas; Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey VA Medical Center, Houston, Texas; Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas; Texas Medical Center Digestive Disease Center, Baylor College of Medicine, Houston, Texas; Center for Translational Research in Inflammatory Diseases, Michael E. DeBakey VA Medical Center, Houston, Texas
| | - Aaron P Thrift
- Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas; Texas Medical Center Digestive Disease Center, Baylor College of Medicine, Houston, Texas
| | - Fasiha Kanwal
- Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas; Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey VA Medical Center, Houston, Texas; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas; Texas Medical Center Digestive Disease Center, Baylor College of Medicine, Houston, Texas
| | - Jessica Davila
- Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey VA Medical Center, Houston, Texas; Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas
| | - Hashem B El-Serag
- Section of Gastroenterology and Hepatology, Department of Medicine, Baylor College of Medicine, Houston, Texas; Center for Innovations in Quality, Effectiveness, and Safety, Michael E. DeBakey VA Medical Center, Houston, Texas; Section of Health Services Research, Department of Medicine, Baylor College of Medicine, Houston, Texas; Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, Texas; Texas Medical Center Digestive Disease Center, Baylor College of Medicine, Houston, Texas.
| |
Collapse
|